Jonathan Biller - 18 Feb 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Financial Officer
Signature: /s/ William Cook, as Attorney in Fact for Jonathan Biller
Issuer symbol: AGIO
Transactions as of: 18 Feb 2022
Net transactions value: -$78,167
Form type: 4
Filing time: 23 Feb 2022, 15:10:52 UTC
Previous filing: 14 Feb 2022
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+8,523	+50%	$0.000000	25,641	18 Feb 2022	Direct
transaction	AGIO	Common stock	Tax liability	$78,167	-2,688	-10%	$29.08	22,953	22 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Performance share units	Options Exercise	$0	-8,523	-50%	$0.000000	8,522	18 Feb 2022	Common stock	8,523		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
F2	The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Content

Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.